Sökning: onr:"swepub:oai:gup.ub.gu.se/58569" >
Factors important f...
-
Baumann, PiaKarolinska Institutet
(författare)
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
- Artikel/kapitelEngelska2006
Förlag, utgivningsår, omfång ...
-
2009-07-08
-
Informa UK Limited,2006
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/58569
-
https://gup.ub.gu.se/publication/58569URI
-
https://doi.org/10.1080/02841860600904862DOI
-
https://lup.lub.lu.se/record/686129URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1938655URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
We reviewed results of SBRT treatment of 138 patients with medically inoperable stage I NSCLC treated during 1996-2003 at five different centres in Sweden and Denmark. Mean age was 74 years (range 56-90) with 69 men and 72 women. SBRT was delivered using a 3D conformal multifield technique and a stereotactic body frame. Doses delivered were 30-48 Gy (65% isodose at the periphery of planning target volume, PTV) in 2-4 fractions. Equivalent dose in 2 Gy fractions (EQD2) was in the range of 50-100 Gy. Mean gross tumour volume (GTV) was 39 cm3 (2-436), and planning target volume was 101 cm3 (11-719). Overall response rate (CR, PR) was 61% (84/138). SD was noted in 36% (50/138). During a median follow-up period of 33 months (1-107), 16 (12%) local failures occurred, ten of which also included distant metastases. Local failure was associated with tumour size, target definition and central or pleura proximity. Distant metastases occurred in 25% (35/138) of the patients. Ninety-one (65%) patients died during follow-up of which 55 patients (60%) died of other causes than lung cancer. Three- and 5-year overall survival was 52 and 26% respectively. Lung cancer specific 3- and 5-year overall survival was 66 and 40% respectively. Fifty nine percent (83/138) of the patients had no side effects. Fourteen patients experienced grade 3-4 toxicity according to radiation therapy oncology group (RTOG). EQD2 (> v.s.<55.6 Gy) showed a statistically significant benefit survival for the higher doses. SBRT for stage I NSCLC results in favourable local control not inferior to fractionated RT and with acceptable toxicity.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nyman, Jan,1956Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xnymja
(författare)
-
Lax, IngmarKarolinska Institutet
(författare)
-
Friesland, SigneKarolinska Institutet
(författare)
-
Hoyer, Morten
(författare)
-
Rehn Ericsson, Suzanne
(författare)
-
Johansson, Karl-AxelGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
(författare)
-
Ekberg, Lars
(författare)
-
Morhed, Elisabeth
(författare)
-
Paludan, Merete
(författare)
-
Wittgren, LenaLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)rfa-lwi
(författare)
-
Blomgren, Henrik
(författare)
-
Lewensohn, RolfKarolinska Institutet
(författare)
-
Karolinska InstitutetInstitutionen för kliniska vetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Acta oncologica (Stockholm, Sweden): Informa UK Limited45:7, s. 787-950284-186X1651-226X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Baumann, Pia
-
Nyman, Jan, 1956
-
Lax, Ingmar
-
Friesland, Signe
-
Hoyer, Morten
-
Rehn Ericsson, S ...
-
visa fler...
-
Johansson, Karl- ...
-
Ekberg, Lars
-
Morhed, Elisabet ...
-
Paludan, Merete
-
Wittgren, Lena
-
Blomgren, Henrik
-
Lewensohn, Rolf
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Acta oncologica ...
- Av lärosätet
-
Göteborgs universitet
-
Lunds universitet
-
Karolinska Institutet